KR101650100B1 - Cell permeable mx1 recombinant protein - Google Patents
Cell permeable mx1 recombinant protein Download PDFInfo
- Publication number
- KR101650100B1 KR101650100B1 KR1020150056137A KR20150056137A KR101650100B1 KR 101650100 B1 KR101650100 B1 KR 101650100B1 KR 1020150056137 A KR1020150056137 A KR 1020150056137A KR 20150056137 A KR20150056137 A KR 20150056137A KR 101650100 B1 KR101650100 B1 KR 101650100B1
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- recombinant
- recombinant protein
- present
- delete delete
- Prior art date
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 25
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 25
- 241000700605 Viruses Species 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 241000712461 unidentified influenza virus Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 230000026683 transduction Effects 0.000 claims description 7
- 238000010361 transduction Methods 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 3
- 108010076818 TEV protease Proteins 0.000 claims description 2
- 241000723792 Tobacco etch virus Species 0.000 claims description 2
- 210000001739 intranuclear inclusion body Anatomy 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims 2
- 239000007927 intramuscular injection Substances 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 abstract description 6
- 239000003443 antiviral agent Substances 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 3
- 101150112867 MX1 gene Proteins 0.000 description 40
- 239000013598 vector Substances 0.000 description 9
- 230000009385 viral infection Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 101710149951 Protein Tat Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000005727 virus proliferation Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 3
- 108091006109 GTPases Proteins 0.000 description 3
- CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical compound [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 2
- 101150019028 Antp gene Proteins 0.000 description 2
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 2
- DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 description 2
- NRVQLLDIJJEIIZ-VZFHVOOUSA-N Cys-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CS)N)O NRVQLLDIJJEIIZ-VZFHVOOUSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- -1 Vp22 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- QVVDVENEPNODSI-BTNSXGMBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylidene Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QVVDVENEPNODSI-BTNSXGMBSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- LJFNNUBZSZCZFN-WHFBIAKZSA-N Ala-Gly-Cys Chemical compound N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)O LJFNNUBZSZCZFN-WHFBIAKZSA-N 0.000 description 1
- QKHWNPQNOHEFST-VZFHVOOUSA-N Ala-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C)N)O QKHWNPQNOHEFST-VZFHVOOUSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- HAYVTMHUNMMXCV-IMJSIDKUSA-N Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CS HAYVTMHUNMMXCV-IMJSIDKUSA-N 0.000 description 1
- CVLIHKBUPSFRQP-WHFBIAKZSA-N Cys-Gly-Ala Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C)C(O)=O CVLIHKBUPSFRQP-WHFBIAKZSA-N 0.000 description 1
- URDUGPGPLNXXES-WHFBIAKZSA-N Cys-Gly-Cys Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O URDUGPGPLNXXES-WHFBIAKZSA-N 0.000 description 1
- OXOQBEVULIBOSH-ZDLURKLDSA-N Cys-Gly-Thr Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O OXOQBEVULIBOSH-ZDLURKLDSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016229 Dynamin GTPase effector Human genes 0.000 description 1
- 108050004749 Dynamin GTPase effector Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108010026288 GTP Phosphohydrolases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 1
- VNBNZUAPOYGRDB-ZDLURKLDSA-N Gly-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN)O VNBNZUAPOYGRDB-ZDLURKLDSA-N 0.000 description 1
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 1
- 101000763951 Homo sapiens Mitochondrial import inner membrane translocase subunit Tim8 A Proteins 0.000 description 1
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100078999 Mus musculus Mx1 gene Proteins 0.000 description 1
- 101001123852 Mus musculus Sialidase-2 Proteins 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 101150042501 PTD gene Proteins 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 1
- WYKJENSCCRJLRC-ZDLURKLDSA-N Thr-Gly-Cys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O WYKJENSCCRJLRC-ZDLURKLDSA-N 0.000 description 1
- XPNSAQMEAVSQRD-FBCQKBJTSA-N Thr-Gly-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)NCC(O)=O XPNSAQMEAVSQRD-FBCQKBJTSA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000023401 ribonucleoprotein complex assembly Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A61K47/48238—
-
- A61K47/48369—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to an Mx1 recombinant protein having increased cell permeability and a use thereof. Since the Mx1 recombinant protein according to the present invention has an increased cell permeability and thus shows a protective effect against various kinds of viruses directly in a host cell, And can be used as an effective antiviral agent against various viruses.
Description
The present invention relates to an Mx1 recombinant protein having increased cell permeability which has a protective effect against influenza virus and its use.
In 1962, after Lindenmann discovered that A2G mice were resistant to Influenza virus infection, a variety of follow-up studies were conducted to determine the cause of resistance. Mx (Myxovirus (influenza virus) resistance) protein, a type of GTPases (Dynamin-like large guanosine triphosphatases) that is induced by a variety of RNA viruses plays an important role in promoting the antiviral mechanism against infection of various RNA viruses (Genome Res 12, 2002, 527-530).
Mx1, a GTPase of mouse, is a nucleotide protein composed of 631 amino acids. It contains a GTPase domain, a Dynamin GTPase effector domain, a Leucine zipper element, And a nuclear localization signal. Mutation analysis for each of the domains revealed that GTP binding elements and nuclear locus signals are essential for the anti-influenza virus effect of the Mx1 protein, and that the Mx1 protein is a functional virus It has been shown that the function of anti-influenza virus is inhibited by the binding of PB2 and NP, the proteins constituting the influenza virus, in the process of functional viral ribonucleoprotein complex assembly (Journal of Virology 86 (24), 2012, 13445-13455).
This Mx1 protein was expected to be used as an antiviral agent by inhibiting the virus activation and inhibiting the virus activation by participating in the innate immune response to various virus infections. However, since the Mx1 protein can not be smoothly transferred into the cell, It is a fact that it does not become.
On the other hand, the eukaryotic cells are surrounded by the cell membrane of the phospholipid bilayer. Due to the hydrophobicity inside the bilayer, it is almost impossible for the hydrophilic substances outside the cell to pass through the cell membrane and move into the cell. Helping. Among them, the protein transduction domain (PTD) is a peptide composed of about 10 basic amino acids, and it is well known that it can bind to various substances such as proteins, peptides, DNA, and move substances into cells without special receptors . Protein transfer by PTD was first detected in the Tat protein of HIV-1 (human immunodeficiency virus-1). The amino acid sequence of the PTD of HIV-1 Tat was found to be the 49-57th RKKRRQRRR, which is the smallest unit that causes free movement of the cell membrane. Recently, various sequence PTDs have been actively developed through subsequent studies.
The present invention aims at using Mx1 protein as an effective antiviral agent, and it is an object of the present invention to provide Mx1 recombinant protein having increased cell permeability and its use.
However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.
Hereinafter, various embodiments described herein will be described with reference to the drawings. In the following description, for purposes of complete understanding of the present invention, various specific details are set forth, such as specific forms, compositions, and processes, and the like. However, certain embodiments may be practiced without one or more of these specific details, or with other known methods and forms. In other instances, well-known processes and techniques of manufacture are not described in any detail, in order not to unnecessarily obscure the present invention. Reference throughout this specification to "one embodiment" or "embodiment" means that a particular feature, form, composition, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Accordingly, the appearances of the phrase " in one embodiment "or" an embodiment "in various places throughout this specification are not necessarily indicative of the same embodiment of the present invention. In addition, particular features, forms, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.
In the present specification, a protein transduction domain (PTD) is a peptide consisting of 3 to 30 amino acids and binds to various substances such as proteins, peptides, and DNA, thereby allowing a peptide capable of transferring substances into cells without special receptors It says. (SEQ ID NO: 4), a trans-activator of transcription (Tat), SEQ ID NO: 5 (YGRKKRRORRR), ANTP (SEQ ID NO: 7: RQIKIWFQNRRMKWKK), a sequence having 5 to 10 arginine 1 (SEQ ID NO: 10: KETWWETWWTEWSQPKKKRKV), Pep-2 (SEQ ID NO: 6: KETWFETWFTEWSQPKKKRKV), but can bind to the Mx1 protein to form a cell membrane There is no restriction as long as it is a domain through which the Mx1 protein can be transferred into the cell.
In this specification, the term "antivirus" refers to a prophylactic or therapeutic action against viral infection that is parasitic on living cells such as animals, plants, bacteria, The virus to be inhibited is not limited, but preferably refers to a virus belonging to orthomyxoviridae and an influenza virus.
The present invention provides a cell permeable Mx1 recombinant protein in which a protein transduction domain (PTD) is bound to one side of a Myxovirus resistance 1 (Mx1) protein.
In one embodiment of the present invention, the protein transduction domain may be an arginine binding sequence, Tat, ANTP, Vp22, MTS, Pep-1, Pep-2 or the like. However, there is no restriction as long as it is a domain capable of binding a protein bound to the Mx1 protein through the cell membrane and transferring it to the interior of the cell.
In another embodiment of the present invention, the recombinant protein may be labeled on one side of the protein for ease of separation. The label may be a histidine-tag, an immunoglobulin Fc region, or the like, but is not limited thereto.
In another embodiment of the present invention, the immunoglobulin Fc gene may be combined with a tobacco etch virus nuclear inclusion endopeptase (TEV protease) sequence so that it can be removed from the cells.
The present invention also provides a polynucleotide encoding the cell permeable Mx1 recombinant protein.
The present invention also provides a recombinant expression vector comprising the polynucleotide. The expression vector may be used for eukaryotic cells or bacteria, but is not limited thereto.
The present invention also provides a pharmaceutical composition for antiviral therapy comprising a cell permeable Mx1 recombinant protein.
In the present invention, the pharmaceutical composition may be in the form of capsules, tablets, granules, injections, ointments, powders or beverages. The pharmaceutical composition may be a human.
The pharmaceutical composition of the present invention may be formulated in the form of oral preparations such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories and sterilized injection solutions according to a conventional method, have. The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be a binder, a lubricant, a disintegrant, an excipient, a solubilizing agent, a dispersing agent, a stabilizer, a suspending agent, a coloring matter, a perfume or the like in the case of oral administration. A solubilizing agent, an isotonic agent, a stabilizer and the like may be mixed and used. In the case of topical administration, a base, an excipient, a lubricant, a preservative and the like may be used. Formulations of the pharmaceutical compositions of the present invention may be prepared in a variety of ways by mixing with pharmaceutically acceptable carriers as described above. For example, oral administration may be in the form of tablets, troches, capsules, Elixir, suspensions, syrups, wafers, etc. In the case of injections, they may be formulated in unit dosage ampoules or in multiple dosage forms have. Other, solutions, suspensions, tablets, capsules, sustained-release preparations and the like.
Examples of suitable carriers, excipients and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltoditol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil. Further, it may further include a filler, an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, an antiseptic, and the like.
The pharmaceutical composition of the present invention varies depending on various factors including the activity of the specific compound used, age, weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease to be prevented or treated. And the dose of the pharmaceutical composition may be appropriately selected by a person skilled in the art depending on the condition of the patient, the body weight, the degree of disease, the type of drug, the route of administration and the period of time, and may be 0.0001 to 50 mg / kg or 0.001 to 50 mg / kg. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way. The pharmaceutical composition according to the present invention can be formulated into pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions.
The Mxl recombinant protein according to the present invention is expected to be used as an effective antiviral agent against various kinds of viruses by increasing cell permeability.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic representation of a recombinant vector for bacteria according to an embodiment of the present invention. FIG.
2 is a result of confirming intracellular introduction of the recombinant Mx1 protein according to an embodiment of the present invention.
FIG. 3 is a graph showing in vitro inhibitory effect of recombinant Mx1 protein on influenza virus and showing the effect of inhibiting virus multiplication by recombinant Mx1 protein. FIG.
FIG. 4 is a graph showing in vitro inhibitory effect of recombinant Mx1 protein on influenza virus, showing inhibitory effect of recombinant Mx1 protein on viral gene expression. FIG.
FIG. 5 is a graph showing the inhibitory effect of recombinant Mx1 protein on influenza virus in vitro, showing inhibition of virus proliferation upon treatment of cells with various concentrations of recombinant Mx1 protein.
FIG. 6 is a graph showing that the survival rate of influenza virus infection is improved in a mouse to which recombinant Mx1 protein is administered, as a result of in vivo examination of the protective effect of recombinant Mx1 protein against influenza virus.
Hereinafter, the present invention will be described in more detail with reference to Examples. It will be apparent to those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
Example 1: Production of recombinant Mx1 expression vector
The present inventors have found that a recombinant expression vector comprising a sequence encoding a cell permeable protein, to which a protein transduction domain sequence is bound to one side of a whole sequence of a mouse-derived Myxovirus resistance 1 (Mx1) .
Specifically, according to a preferred embodiment of the present invention, 9 arginine (PTD sequence (SEQ ID NO: 4)) is added to the 3 'terminal region of the mouse-derived myxvirus resistance gene sequence (SEQ ID NO: 1) (NheI and NotI) cleavage sites, the PCR is carried out using the novel primer sequences SEQ ID NOS: 2 and 3 as forward and backward primers. The primer sequence can be hybridized at the end of the template Mx1 sequence to form a double-stranded structure.
A variety of DNA polymerases can be used in the PCR process, and the polymerase used is a thermostable DNA polymerase from T7 polymerase from various bacteriophages or from a variety of bacteria, including Thermus aquaticus, Taq), Thermus thermophilus (Tth), and Pyrococus furious (pfu).
When carrying out the polymerization reaction, buffer solutions are used which contain co-factors such as Mg 2 + and dNTPs including dATP, dTTP, dCTP and dGTP sufficiently and the polymerase reaction can take place under optimal conditions.
After the polymerase chain reaction, restriction enzymes and DNA joining enzymes were used to insert the amplified sequences into the vector. Specifically, the present inventors used E. coli overexpressing vector pET28a. The pET28a vector itself contains a His tag at the multiple restriction site so that a His tag that facilitates protein extraction can be coupled to the recombinant protein. The PCR products and vectors were treated with Nhe I and Not I restriction enzymes and the PCR products were inserted into the vector using T4 DNA ligase. Finally, recombinant proteins having the same structure as in FIG. 1 were expressed in this vector . The vector expressing the recombinant Mx1 protein prepared through such a process was named pET28a-His-Mx1-9R expression vector.
Example 2: Expression of pET28a-His-Mx1-9R in E. coli
The pET28a-His-Mx1-9R vector prepared in Example 1 was transformed into Escherichia coli BL21 (DE3) (Enzynomics) and cultured in LB solid medium containing kanamycin for 12 hours at 37 ° C. A single colony formed at this time was inoculated into LB liquid medium containing kanamycin and incubated at 37 ° C. for 3 hours. The culture was cooled to 18 ° C. and then IPTG (Isopropyl-β-D-thiogalactopyranoside) 0.1 mM concentration, and further cultured for 18 hours to express Mx1 recombinant protein added with PTD sequence.
The culture was centrifuged at high speed and the precipitated cells were suspended in a lysis buffer and dissolved using an ultrasonic generator. The lysis buffer used contained Tris-HCl, NaCl, and imidazole, and PMSF (Phenylmethanesulfonylfluoride), a protease inhibitor, was added to prevent protein degradation. The lysed cells were again centrifuged at high speed and the supernatant was added to Ni-IDA (agarose resin column) to adsorb the protein on the resin. Subsequently, the eluted buffer solution containing excess imidazole was added to separate and extract the recombinant protein adsorbed on the resin, and the filtered recombinant protein was confirmed on an 8% SDS-PAGE gel.
The recombinant Mx1-9R expressed in the above procedure formed a large amount of insoluble inclusion bodies at the time of expression, but the yield of the water-soluble proteins could be increased by lowering the expression temperature to 18 ° C.
Example 3: Confirmation of intracellular introduction of recombinant Mx1 protein Mx1-9R
This recombinant protein was inoculated into MDCK (Madin-darby canine kidney) cells at various concentrations and time to confirm the ability of the recombinant Mx1 protein Mx1-9R having the PTD sequence extracted in Example 2 to intracellularly. Since the recombinant protein Mx1-9R expresses His, it was confirmed by flow cytometry how much Mx1-9R was introduced into the inoculated cells. Specifically, Mx1-9R was inoculated into MDCK cells, cultured at 37 ° C., and cells inoculated 12 hours or 24 hours later. The cells were washed with PBS, and the extra Mx1-9R not introduced was removed. Cell fixation and permeabilization kit was used to immobilize the cells and to impart permeability, and a His-specific antibody And the Mx1-9R protein present in the cells was confirmed using a flow cytometer. As a result, it was observed that the recombinant Mx1 protein Mx1-9R was introduced into the cells at a concentration of 50 μg / ml and 100 μg / ml after 12 hours (FIG. 2).
Example 4: Confirmation of virus infection resistance of recombinant Mx1 protein
After confirming that the recombinant Mx1 protein Mx1-9R was introduced into cells through Example 3, the effect of the Mx1 protein introduced into the cells on the viral infection-defying ability of the cells was confirmed. Specifically, Mx1-9R at a concentration of 50 μg / ml was treated with MDCK cells 12 hours before the infection and cultured at 37 ° C., and infected with influenza virus PR8 at 0.01 or 0.1 MOI (multiplicity of infection). After incubation for 48 hours at 37 ° C, the virus concentration in the culture medium was measured using a plaque assay method. The mRNA of the cells was extracted and the cDNA was synthesized using reverse transcriptase. The expression of the viral RNA was analyzed by qPCR Respectively. As a result, it was confirmed that when the recombinant Mx1 protein Mx1-9R was treated, virus proliferation was inhibited by 7 times at 0.1 MOI infection and 30 times at 0.01 MOI infection as compared with the control group as shown in FIG. 3 (p value < 0.001). It was observed that the expression of NP (nucleoprotein), a viral gene, decreased from 8 times at 0.1 MOI infection to 54 times at 0.01 MOI infection (Fig. 4).
In order to examine the effect of MDCK cells treated with various concentrations of Mx1-9R on influenza virus infection, the degree of inhibition of virus proliferation was examined. Twenty-two hours before infection, 50-125 μg / ml recombinant Mx1-9R The cells were treated and infected with 0.01 MOI of influenza virus. After 48 hours, the amount of virus in the culture solution was measured. As a result, a 6 to 9-fold inhibition of virus proliferation was observed for Mx1 protein (p value <0.05) (Fig. 5).
Example 5
It was confirmed that the recombinant Mx1 protein introduced into the cell via Mx1-9R enhances the ability to protect against influenza virus infection through Example 4, and it is verified whether the same effect is also exerted in vivo using the mouse. Specifically, 1 μg of recombinant Mx1 protein per mouse was administered into the nasal cavity, and after 24 hours, 25 PFU of influenza virus PR8 was infected intranasally and the survival rate of the mice was measured. At this time, mice in which PBS was intranasally administered and infected with 25 PFU of influenza virus PR8 in the nasal cavity after 24 hours were used as a control for the evaluation of the survival rate. Euthanasia was defined as the end of the experiment when the survival rate was measured. When the body weight of the mice decreased by 25% or more compared with the day of virus infection, euthanasia was performed. As a result, it was confirmed that the recombinant protein Mx1-9R increased the ability to protect against influenza virus infection in vivo as well (P value <0.05) ).
<110> Korea Advanced Institute of Science And Technology (Kaist) <120> CELL PERMEABLE MX1 RECOMBINANT PROTEIN <130> DPB140013.k01 <150> KR KR 14/048110 <151> 2014-04-22 <160> 4 <170> Kopatentin 2.0 <210> 1 <211> 1896 <212> DNA <213> Mouse_Mx1 gene <400> 1 atggattctg tgaataatct gtgcaggcac tatgaggaga aggtgcggcc ctgtattgac 60 ctcatcgaca ccctgagggc tctgggtgtg gagcaggacc tggccctgcc tgccatcgct 120 gtcattgggg accagagttc agggaagagc tctgttctgg aagcactgtc tggagtggcc 180 ctccccagag gcagtggtat tgtcaccaga tgccctctgg tgctgaaatt gaggaagctg 240 aaagaaggag aggagtggag aggcaaagtc tcctatgatg acatcgaagt ggagctctct 300 gatccttcag aggtggaaga ggccattaac aagggtcaga acttcattgc tggggtaggc 360 ctggggatca gtgataagct cattagcctg gatgtcagct ccccaaatgt cccagacctg 420 actctcattg acctgcctgg aattaccagg gtggctgtag gcaaccagcc tgcagacata 480 ggacgccaga tcaagagact tatcaagaca tacatccaaa aacaagagac catcaacctg 540 gtggtagtcc ccagcaatgt ggacattgct accacagagg ctctgagcat ggctcaggag 600 gtggaccctg aaggggatag gaccataggg gtcttgacca agcctgatct ggtggacaga 660 ggtgctgaag gcaaggtctt ggatgtgatg cggaacctgg tgtatcctct gaagaagggc 720 tacatgatag tcaagtgcag aggtcagcag gacatccaag agcagctgag cctgactgag 780 gcttttcaga aagagcaagt cttcttcaag gatcactcat acttcagcat tcttctggaa 840 gatgggaagg ccacagtgcc ctgcctggca gagagactga ctgaggagct cacctcccac 900 atctgtaaat cactgccact attggaagat caaataaata gcagtcatca gagtgcaagc 960 gaggagctgc agaagtacgg tgcagacata ccagaagatg acagaacgag gatgtccttt 1020 ctggtgaata aaatcagtgc cttcaatagg aatatcatga atttgataca agcacaggaa 1080 accgtatcag agggagacag ccggttgttt accaaactgc gaaatgagtt tcttgcttgg 1140 gatgatcata ttgaggaata ttttaaaaaa gattctcctg aggtacaaag caagatgaaa 1200 gaatttgaaa atcagtatcg tggccgggag ctgccagggt ttgtggacta caaggcattt 1260 gagagcatca tcaaaaagcg agtcaaagcc ctggaagagt ctgctgtgaa catgctgcgc 1320 agggtcacta agatggtcca aactgccttc gtaaagattt tatcaaatga ttttggtgat 1380 tttttaaacc tctgctgtac tgctaagtcc aaaattaaag aaataagatt aaaccaagaa 1440 aaggaagctg aaaacctgat ccgacttcac ttccagatgg aacagattgt ctactgccag 1500 gaccaggttt acaaggaaac cttgaagacg atcagagaga aggaagctga gaaagagaag 1560 accaaggcat taataaaccc tgctaccttt caaaataact ctcagtttcc tcaaaagggg 1620 ttgactacca ctgagatgac ccagcacctg aaagcctact accaggagtg cagacggaat 1680 attgggagac agatccctct gattatccag tacttcatcc tgaaaacatt tggggaggaa 1740 atagagaaaa tgatgcttca gcttttacag gacaccagta agtgcagctg gttcctggag 1800 gagcagagtg acaccagaga gaagaagaag ttcctgaaaa ggcggctttt aaggctggat 1860 gaggctcggc agaagcttgc caaattctcc gattaa 1896 <210> 2 <211> 34 <212> PRT <213> Nhe1_mutant_primer 5 ' <400> 2 Cys Thr Ala Gly Cys Thr Ala Gly Cys Ala Thr Gly Gly Ala Thr Thr 1 5 10 15 Cys Thr Gly Thr Gly Ala Ala Thr Ala Ala Thr Cys Thr Gly Thr Gly 20 25 30 Cys Ala <210> 3 <211> 61 <212> PRT <213> Not1_mutant_primer 3 ' <400> 3 Ala Thr Ala Ala Gly Ala Ala Thr Gly Cys Gly Gly Cys Cys Gly Cys 1 5 10 15 Cys Thr Ala Gly Cys Gly Gly Cys Gly Thr Cys Thr Gly Cys Gly Thr 20 25 30 Cys Thr Gly Cys Gly Gly Cys Gly Thr Cys Thr Gly Cys Gly Ala Thr 35 40 45 Cys Gly Gly Ala Gly Aly Ala Thr Thr Thr Gly Gly Cys 50 55 60 <210> 4 <211> 9 <212> PRT <213> Protein transduction domain <400> 4 Arg Arg Arg Arg Arg Arg Arg Arg Arg 1 5
Claims (15)
Wherein the recombinant protein has a histidine-tag bound to the 5 'end of the recombinant protein.
Wherein the immunoglobulin Fc region gene is bound to the 5 'end of the recombinant protein.
Wherein the immunoglobulin Fc gene is linked to a Tobacco etch virus nuclear inclusion endopeptase (TEV protease) sequence.
Wherein said pharmaceutical composition is characterized in that it is for treating or preventing an infection in influenza virus.
Wherein said pharmaceutical composition is administered intravenously by intravenous injection, intramuscular injection, intramuscular injection, subcutaneous injection, intraconjugate injection, transdermal delivery or airway inhalation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140048110 | 2014-04-22 | ||
| KR1020140048110 | 2014-04-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150122088A KR20150122088A (en) | 2015-10-30 |
| KR101650100B1 true KR101650100B1 (en) | 2016-08-23 |
Family
ID=54431013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150056137A KR101650100B1 (en) | 2014-04-22 | 2015-04-21 | Cell permeable mx1 recombinant protein |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101650100B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102145793B1 (en) * | 2019-04-01 | 2020-08-19 | 한국과학기술원 | Pharmaceutical compositions for the prevention or treatment of influenza virus infection |
| KR102494231B1 (en) * | 2020-07-13 | 2023-02-03 | 한국과학기술원 | Pharmaceutical compositions for the prevention or treatment of influenza virus infection |
| KR102560134B1 (en) | 2021-04-01 | 2023-07-27 | 가톨릭대학교 산학협력단 | Cell permeable Regnase-1 recombinant protein and anti-inflammatory composition comprising the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007027557A2 (en) * | 2005-08-30 | 2007-03-08 | Illumigen Biosciences, Inc. | Detection of mutations in a gene associated with resistance to viral infection, mx1 |
-
2015
- 2015-04-21 KR KR1020150056137A patent/KR101650100B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007027557A2 (en) * | 2005-08-30 | 2007-03-08 | Illumigen Biosciences, Inc. | Detection of mutations in a gene associated with resistance to viral infection, mx1 |
| US20090155234A1 (en) | 2005-08-30 | 2009-06-18 | Cubist Pharmaceuticals, Inc. | Detection of mutations in a gene associated with resistance to viral infection, mx1 |
Non-Patent Citations (1)
| Title |
|---|
| Zhang X-m. et al., Antiviral Research 99:pp.149-157 (2013. 5.28.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150122088A (en) | 2015-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Praefcke | Regulation of innate immune functions by guanylate-binding proteins | |
| Hale et al. | The multifunctional NS1 protein of influenza A viruses | |
| US8592556B2 (en) | Phage φmru polynucleotides and polypeptides and uses thereof | |
| US11746133B2 (en) | Cell penetrating peptides that inhibit IRF5 nuclear localization | |
| SA518400172B1 (en) | Multivalent vaccines for rabies virus and coronaviruses | |
| JP2017521425A (en) | Influenza virus vaccine and use thereof | |
| KR101650100B1 (en) | Cell permeable mx1 recombinant protein | |
| WO2009095500A1 (en) | Inhibitors of lentiviral replication | |
| CN108697764A (en) | The pharmaceutical composition for preventing or treating influenza infection of interleukin 7 fusion protein is merged containing immunoglobulin FC | |
| JPH07503230A (en) | Drugs for the treatment of papillomavirus diseases | |
| US8440788B2 (en) | N-terminal VDAC variants and uses thereof | |
| US20110142811A1 (en) | Measles virus for the elimination of unwanted cell populations | |
| KR101783030B1 (en) | Pharmaceurical composition for preventing or treating hepatitis C virus infection or disease due to HCV infection | |
| PT1200132E (en) | Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines | |
| KR102061324B1 (en) | Cell permeable mx-a recombinant protein | |
| KR102145793B1 (en) | Pharmaceutical compositions for the prevention or treatment of influenza virus infection | |
| KR102259320B1 (en) | Pharmaceutical Composition for Preventing or Treating Influenza Virus Infection Disease | |
| JP2009506025A (en) | Antiviral agent and viral replication inhibitor | |
| US20190367567A1 (en) | Peptides and Uses for Managing Viral Infections | |
| RU2813150C2 (en) | Isolated recombinant virus based on influenza virus for inducing specific immunity to influenza virus and/or preventing diseases caused by influenza virus | |
| Xiao | Influenza A virus interferes with innate immune signaling in avian cells | |
| CA2380354A1 (en) | Novel tachykinin peptides, precursor peptides thereof and genes encoding the same | |
| WO2023081913A1 (en) | Wild boar cathelicidin peptide variants and vectors encoding the same for uses in managing coronavirus infections | |
| CN115835906A (en) | Novel immunomodulator | |
| WO2015107357A1 (en) | Assay and medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20190725 Year of fee payment: 4 |